151
Participants
Start Date
August 23, 2017
Primary Completion Date
October 26, 2023
Study Completion Date
October 26, 2023
H3B-6545
Oral capsules by mouth once daily
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Hopital Jean Minjoz, Besançon
University of North Carolina, Chapel Hill
Southeastern Regional Medical Center, Inc., DBA Cancer Treatment Centers of America, Atlanta, Newnan
Holy Cross Hospital Inc, Fort Lauderdale
Florida Cancer Specialists North, St. Petersburg
Florida Cancer Specialists South, Fort Myers
Florida Cancer Specialists and Research Institute, Sarasota
EDOG - Centre Eugene Marquis Centre Regional de Lutte Contre Le Cancer - PPDS, Rennes
Tennessee Oncology, Nashville
EDOG Institut de Cancerologie de l'Ouest - PPDS, Saint-Herblain
University of Michigan, Ann Arbor
Edog - Ico - Ppds, Angers
Centre Oscar Lambret, Lille
Midwestern Regional Medical Center, Inc., DBA Cancer Treatment Centers of Americal, Chicago, Zion
Carle Cancer Center, Urbana
Centre Jean Perrin, Clermont-Ferrand
Saint Luke's Cancer Institute, Kansas City
Research Medical Center, Kansas City
Institut de Cancérologie Strasbourg Europe, Strasbourg
Hôpital Saint Louis, Paris
Hôpital de la Pitié Salpétrière, Paris
Parkland Health and Hospital System, Dallas
UT Southwestern Medical Center, Dallas
Tyler Oncology/Oncology PA, Tyler
University of Colorado - Cancer Center, Aurora
Huntsman Cancer Institute at The University of Utah, Salt Lake City
Western Regional Medical Center, Inc., DBA Cancer Treatment Centers of America, Phoenix, Goodyear
Comprehensive Cancer Center of Nevada, Las Vegas
University of California Los Angeles, Los Angeles
University of California San Francisco, San Francisco
Institut Gustave Roussy, Villejuif
Massachusetts General Hospital, Boston
The Royal Marsden NHS Foundation Trust, Chelsea
Velindre Cancer Centre, Cardiff
Barts Health NHS Trust, London
Sarah Cannon Research Institute, London
Christie Hospital, Manchester
The Royal Marsden NHS Foundation Trust, Sutton
Eisai Inc.
INDUSTRY